ENGAGE run · 37eef4d73774

```json [ { "post_index": 0, "cluster_ids": [24], "claim": "J-1 visa delays force U.S.-trained international physicians to leave healthcare system", "argument_type": "empirical_claim", "stance": "challenges_status_quo", "hyde_excerpt": "The J-1 visa waiver program delays are creating an unintended physician supply shock in safety-net and rural healthcare delivery. As hund

```json [ { "post_index": 17, "matched_article_id": 453, "match_confidence": 87, "match_reason": "The tweet argues that AI drug discovery models overfit on positive binding data due to lack of published null results — directly addressing the article's thesis that AI has compressed preclinical discovery but exposed downstream evidence infrastructure failures, including training da

Roughly one in five real-world oncology patients would not qualify for the phase 3 trials that generated the binding and efficacy data these models are trained on, which means the selection problem runs deeper than just missing negatives. The training data gap you're describing (molecules that failed to bind) has a structural cousin in clinical translation: the populations that generated positive

The diagnostic accuracy finding is real and the research is solid. But there's a structural problem sitting right underneath it that this framing skips over entirely. When an LLM outperforms a physician and the physician follows that recommendation and the patient is harmed anyway, the physician gets sued. The LLM vendor does not. That's not hypothetical, that's the current contractual and regula

The build cost was prohibitive, so you bought a vendor platform instead. That vendor's moat was never the idea, it was that you couldn't afford to replicate it. That's the exact dynamic I traced through healthcare in https://www.onhealthcare.tech/p/the-free-lunch-is-over-except-now?utm_source=x&utm_medium=reply&utm_content=2050684160151617603&utm_campaign=the-free-lunch-is-over-except-now, where a

The 2013 ACC/AHA guideline shift alone added an estimated 12.8 million newly statin-eligible Americans overnight, and the calculator used to justify it was later shown to overestimate cardiovascular risk by 75-150% in external validation cohorts. But the threshold-moving dynamic you're describing is actually the mechanism that makes cost-plus drug pricing so disruptive as a business model. When g

```json [] ```

```json [] ```

```json [ {"post_index": 0, "prediction": "reject", "confidence": 92, "reason": "Non-healthcare content, vague praise without substance"}, {"post_index": 1, "prediction": "reject", "confidence": 95, "reason": "Airline link, not healthcare-related"}, {"post_index": 2, "prediction": "reject", "c

```json [ { "category": "ai_safety_vulnerability_incident_tangential", "summary": "Posts about AI safety incidents, security breaches, or vulnerability exploits that lack healthcare system context or application.", "exclusion_rule": "Exclude posts describing AI model vulnerabilities, s